Samsung Biologics, of Incheon, South Korea, said the FDA has licensed the first monoclonal antibody drug substance at its second plant. The company is now able to manufacture commercial biologics drug substance in addition to its first plant, which has 30,000 liters of capacity. The second plant has 152,000 liters of capacity.